Prosecution Insights
Last updated: November 20, 2026

Daniel John Burkett, USPTO Patent Examiner

Listed by the USPTO as BURKETT, DANIEL JOHN

Tech Center 3600 • Art Units: 1600 1621 1624 1625 1626 3646

This examiner grants 64% of resolved cases

Analysis

This examiner is in Tech Center 3600 and Art Unit 1600, with 104 resolved cases. The allowance rate is 64.4%, and the median time to allowance is 1219 days. The 32.8% interview lift supports treating interviews as a meaningful component of prosecution strategy.

The principal companies are Institut National de La Sante Et de La Recherche Medicale, The Regents of the University of California, and Hoffmann-La Roche Inc. The leading firms are Conley Rose, P.C., BELL & ASSOCIATES, and Casimir Jones, S.C. Practitioners may combine interview preparation with detailed written responses tailored to the technical record.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

64.4%
Allow Rate
+12.4% vs TC avg
158
Total Applications
+32.8%
Interview Lift
1219
Avg Prosecution Days
Based on 104 resolved cases, 2023–2026

Rejection Statute Breakdown

3.6%
§101 Eligibility
20.6%
§102 Novelty
18.3%
§103 Obviousness
43.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18855254 COMBINATION METABOLIC-EPIGENETIC TREATMENT FOR EARLY LUNG CANCER Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18993989 NOVEL ISOTHIAZOL-3-YL AND ISOXAZOL-3-YL SULFONAMIDE COMPOUNDS Non-Final OA Hoffmann-La Roche Inc.
18691241 MEDICAMENT FOR PREVENTING AND/OR TREATING DRY EYE Final Rejection Boehringer Ingelheim International GMBH
18022962 MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF Final Rejection Massachusetts Institute of Technology
18283264 ENAMINE N-OXIDES: SYNTHESIS AND APPLICATION TO HYPOXIA-RESPONSIVE PRODRUGS AND IMAGING AGENTS Non-Final OA DANA-FARBER CANCER INSTITUTE, INC.
18653324 PENTAMIDINE ANALOGS Non-Final OA THE GENERAL HOSPITAL CORPORATION
18176877 INHIBITION OF URACIL DNA GLYCOSYLASE IN THE OPEN CONFORMATION Non-Final OA CASE WESTERN RESERVE UNIVERSITY
18251101 CRYSTALLINE FORM II OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR Non-Final OA LG CHEM, LTD.
18568761 COMPOUND AS CDK KINASE INHIBITOR AND USE THEREOF Non-Final OA TYK MEDICINES, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Daniel John Burkett's allowance rate?

64.4% of resolved applications examined by Daniel John Burkett were allowed (104 resolved cases), compared with 36.5% across Art Unit 1600 over the last five years.

Does an interview help with examiner Daniel John Burkett?

This examiner's interview lift is +32.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Daniel John Burkett take to allow a patent?

Applications allowed by Daniel John Burkett took 1,219 days on average from filing to allowance.

Which art unit does examiner Daniel John Burkett work in?

Daniel John Burkett examines applications in Art Unit 1600 in Tech Center 3600 (Transportation, E-Commerce & Mechanical Systems).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month